Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/140
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Dextrose (Injection)
|
| dailymed-instance:dosage |
These solutions are for intravenous use only. Dosage is to be directed by a physician and is dependent upon age, weight, clinical condition of the patient and laboratory determinations. Frequent laboratory determinations and clinical evaluation are essential to monitor changes in blood glucose and electrolyte concentrations, and fluid and electrolyte balance during prolonged parenteral therapy. When a hypertonic solution is to be administered peripherally, it should be slowly infused through a small bore needle, placed well within the lumen of a large vein to minimize venous irritation. Carefully avoid infiltration. Fluid administration should be based on calculated maintenance or replacement fluid requirements for each patient. Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques. Mix thoroughly. Do not store. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
|
| dailymed-instance:descripti... |
Each 100 mL of 5% Dextrose Injection USP contains:Hydrous Dextrose USP 5 g; Water for Injection USP qspH: 4.4 (3.5���6.5); Calculated Osmolarity: 250 mOsmol/literCalories per liter: 170 Each 100 mL of 10% Dextrose Injection USP contains:Hydrous Dextrose USP 10 g; Water for Injection USP qspH: 4.4 (3.5���6.5); Calculated Osmolarity: 505 mOsmol/liter, hypertonicCalories per liter: 340 Dextrose Injections USP are sterile, nonpyrogenic and contain no bacteriostatic or antimicrobial agents. These products are intended for intravenous administration. The formula of the active ingredient is: The EXCEL Container is Latex-free; PVC-free; and DEHP-free. The plastic container is made from a multilayered film specifically developed for parenteral drugs. It contains no plasticizers and exhibits virtually no leachables. The solution contact layer is a rubberized copolymer of ethylene and propylene. The container is nontoxic and biologically inert. The container-solution unit is a closed system and is not dependent upon entry of external air during administration. The container is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary. Addition of medication should be accomplished using complete aseptic technique. The closure system has two ports; the one for the administration set has a tamper evident plastic protector and the other is a medication addition site. Refer to the Directions for Use of the container.
|
| dailymed-instance:clinicalP... |
Dextrose Injections USP provide calories and are a source of water for hydration. They are capable of inducing diuresis depending on the clinical condition of the patient. Dextrose is readily metabolized, may decrease losses of body protein and nitrogen, promotes glycogen deposition and decreases or prevents ketosis if sufficient doses are provided. Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult daily requirements range from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production).
|
| dailymed-instance:activeIng... | |
| dailymed-instance:contraind... |
Solutions containing dextrose may be contraindicated in patients with hypersensitivity to corn products.
|
| dailymed-instance:supply |
Dextrose Injections USP are supplied sterile and nonpyrogenic in EXCEL Containers. The 1000 mL containers are packaged 12 per case, the 500 mL and 250 mL containers are packaged 24 per case. Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended that the product be stored at room temperature (25��C); however, brief exposure up to 40��C does not adversely affect the product.
|
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... | |
| dailymed-instance:overdosag... |
In the event of a fluid or solute overload during parenteral therapy, reevaluate the patient's condition and institute appropriate corrective treatment.
|
| dailymed-instance:genericMe... |
Dextrose monohydrate
|
| dailymed-instance:fullName |
Dextrose (Injection)
|
| dailymed-instance:adverseRe... |
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. Too rapid infusion of hypertonic solutions may cause local pain and venous irritation. Rate of administration should be adjusted according to tolerance. Use of the largest peripheral vein and a small bore needle is recommended. (See
DOSAGE AND ADMINISTRATION
.) The physician should also be alert to the possibility of adverse reactions to drug additives. Prescribing information for drug additives to be administered in this manner should be consulted. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.
|
| dailymed-instance:indicatio... |
These intravenous solutions are indicated for use in adults and pediatric patients as sources of calories and water for hydration.
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Dextrose
|